Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility study of neoadjuvant versus adjuvant chemotherapy in upper tract urothelial carcinoma
NL-OMON58769Phase 2Not yet recruiting
- Sponsor
- European Uro-Oncology Group
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gemcitabine and cisplatin in upper tract urothelial carcinoma (UTUC) (3 arms), sponsored by European Uro-Oncology Group. Primary endpoints: Proportion able to start and complete planned chemotherapy, Renal function and fitness for cisplatin-based chemotherapy and 1 more. Planned start May 2018; status: not yet recruiting.
02
Drugs
gemcitabinecisplatin
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NL-OMON58769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58769.